153 related articles for article (PubMed ID: 30569900)
1. Breast cancer and neoadjuvant chemotherapy: indications for and limits of breast-conserving surgery.
Caldana M; Pellini F; Lombardi D; Mirandola S; Invento A; Pollini GP
Ann Ital Chir; 2018; 89():392-397. PubMed ID: 30569900
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.
Krug D; Vladimirova V; Untch M; Kühn T; Schneeweiss A; Denkert C; Ataseven B; Solbach C; Gerber B; Tesch H; Golatta M; Seiler S; Heil J; Nekljudova V; Holtschmidt J; Loibl S
Breast; 2024 Apr; 74():103701. PubMed ID: 38422624
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.
Volders JH; Haloua MH; Krekel NM; Negenborn VL; Barbé E; Sietses C; Jóźwiak K; Meijer S; van den Tol MP;
Eur J Surg Oncol; 2016 Jul; 42(7):986-93. PubMed ID: 27211343
[TBL] [Abstract][Full Text] [Related]
4. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
5. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
7. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of safe breast conservation in large and locally advanced cancers with use of radiopaque markers to mark pre-neoadjuvant chemotherapy tumor margins.
Aggarwal V; Agarwal G; Lal P; Krishnani N; Mishra A; Verma AK; Mishra SK
World J Surg; 2008 Dec; 32(12):2562-9. PubMed ID: 18030518
[TBL] [Abstract][Full Text] [Related]
9. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
10. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
Torrisi R; Marrazzo E; Agostinetto E; De Sanctis R; Losurdo A; Masci G; Tinterri C; Santoro A
Crit Rev Oncol Hematol; 2021 Apr; 160():103280. PubMed ID: 33667658
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
13. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
14. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis.
Sun Y; Liao M; He L; Zhu C
Medicine (Baltimore); 2017 Oct; 96(43):e8367. PubMed ID: 29069026
[TBL] [Abstract][Full Text] [Related]
15. Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery.
Zhang J; Lu CY; Chen HM; Wu SY
Surg Oncol; 2021 Mar; 36():91-98. PubMed ID: 33316685
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R
Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Criscitiello C; Azim HA; Agbor-tarh D; de Azambuja E; Piccart M; Baselga J; Eidtmann H; Di Cosimo S; Bradbury I; Rubio IT
Ann Oncol; 2013 Aug; 24(8):1980-5. PubMed ID: 23567146
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
20. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
